C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

Completed

• Conditions: Cardiovascular Risk

• Registration Number: NCT00921752
• Lead Sponsor: AstraZeneca

Brief Summary

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-06-12
• Study First Submitted QC: 2009-06-15
• Study First Posted: 2009-06-16
• Study Completion: 2009-11
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-03
• Last Update Posted: 2009-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion Criteria

• Not eligible for lipid or statin therapy
• Intolerance to therapy
• Patients at low or intermediate CV risk

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percent rate of patients achieving target LDL cholesterol goals	On each of the 3 visits performed during the study
Percent rate of patients achieving 50% or more reduction in LDL-cholesterol	On each of the 3 visits performed during the study

Secondary Outcome Measures

Name	Time	Method
Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals	On each of the 3 visits performed during the study
Percent rate of compliance among patients in the study	On each of the 3 visits performed during the study

Trial Locations

Locations (1)

Research Site; 🇭🇺 Vac, Hungary